BioCentury | Apr 23, 2020
Finance

Crossovers back Affinivax in $120M series B to broaden clinical vaccine pipeline

Though it once felt it could do without a large cash infusion from VCs, Affinivax has chosen to raise $120 million in a series B round that is designed to advance a handful of preclinical...
BioCentury | Apr 3, 2020
Deals

Servier adds mAb platform via takeout of former European biotech darling Symphogen

What was once a high-profile European biotech is now going out quietly as Servier is acquiring Danish mAb company Symphogen A/S for an undisclosed sum. The two companies are partnered across three clinical stage immuno-oncology...
BioCentury | Apr 1, 2020
Distillery Therapeutics

Two glycopeptides for drug-resistant Gram-positive infections

...INDICATION: Staphylococcus; Gram-positive bacterial infections The glycopeptides corbomycin and complestatin could treat methicillin- and daptomycin-resistant S. aureus...
...Complestatin and corbymycin reduced the growth of a panel of Gram-positive bacteria including MRSA, daptomycin-resistant S. aureus...
BioCentury | Feb 28, 2020
Distillery Therapeutics

Sodium nitrite plus EDTA for bacterial infections

DISEASE CATEGORY: Infectious disease INDICATION: Pseudomonas; Gram-positive bacterial infection; Gram-negative bacterial infection Arch Biopartners’ AB569, a combination of sodium nitrite and ethylenediaminetetraacetic acid (EDTA), could treat infections by Pseudomonas aeruginosa and other bacteria. The two...
BioCentury | Jan 31, 2020
Distillery Therapeutics

Hydrogel-delivered, thrombin-derived peptide to treat and prevent Staphylococcus and Pseudomonas infections

...Staphylococcus ; Pseudomonas A polymer-based hydrogel containing the thrombin-derived peptide TCP-25 could treat and prevent S. aureus...
...shown to bind to and neutralize bacterial LPS, showed a more than three-log reduction of S. aureus...
...vitro and reduced bacterial load in mice when given both before and after inoculation with S. aureus...
BioCentury | Jan 18, 2020
Finance

Novo seeks to REPAIR funding in antibiotics companies

In response to an expanding funding gap for antimicrobial resistance companies, Novo Holdings is expanding the remit of its early stage REPAIR Impact Fund to include investments as late as Phase II for the fund’s...
BioCentury | Jan 18, 2020
Finance

Novo seeks to REPAIR funding in antibiotics companies

In response to an expanding funding gap for antimicrobial resistance companies, Novo Holdings is expanding the remit of its early stage REPAIR Impact Fund to include investments as late as Phase II for the fund’s...
BioCentury | Dec 10, 2019
Company News

Janssen pays $750M for XBiotech's dermatology candidate after positive Phase II data

After searching for a new candidate to add to its immuno-dermatology pipeline, Janssen Biotech Inc. will spend $750 up front to acquire bermekimab, a clinical anti-IL-1α antibody, from XBiotech Inc. The mAb is first being...
BioCentury | Dec 6, 2019
Preclinical News

Dec. 5 Preclinical Quick Takes: Simpler synthesis of Merck’s HIV therapy; plus MRSA antibiotic, once-monthly oral contraceptive

...Nature Chemical Biology article , the benzoyl thiourea-based compound as monotherapy blocked biofilm formation in S. aureus...
BioCentury | Oct 31, 2019
Preclinical News

Oct. 31 Preclinical Quick Takes: Beam licenses tech from Prime Medicine; plus BioVersys, Astellas-Kyoto University and more

...inhibiting the transcription factor AgrA to treat Staphylococcus aureus infections. Instead of directly killing the S. aureus...
...FOXP3) Huntingtin (HTT) Microtubule-associated protein 1 light chain 3 alpha (MAP1LC3A) (LC3A) (LC3) Staphylococcus accessory gene regulator A (S. aureus...
Items per page:
1 - 10 of 1272